Tuberculin antigen

PreclinicalBiologic

HHospices Civils de Lyon

Tuberculin antigen is one of 3 biologic programs targeting Immune System. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune SystemTerminated

Immune SystemPreclinical

Terminated

Competition

Competitive Landscape

2 competitors in Immune System

#DrugCompanyPhaseTrials

Fluzone

GSK

Phase 3

1 2

Pneumococcal 7-Valent Conjugate Vaccine

Sanofi

Preclinical

1 3

Tuberculin antigen

HHospices Civils de Lyon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immune System1 trial

Pathophysiological Study of Characteristics of the Changes in the Cutaneous Immune System After Intradermal Antigen Injections

Terminated·HHospices Civils de Lyon·N/A·NCT00716989·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tuberculin antigen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tuberculin antigen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tuberculin antigen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospices Civils de Lyon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: HHospices Civils de Lyon

Tuberculin antigen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immune System1 trial

References

Drug Info

Quick Facts

Related News